Comparison of sublingual misoprostol, intravenous oxytocin, and intravenous methylergometrine in active management of the third stage of labor.
Int J Gynaecol Obstet
; 107(2): 130-4, 2009 Nov.
Article
em En
| MEDLINE
| ID: mdl-19628206
ABSTRACT
OBJECTIVE:
To compare the efficacy and adverse effects of sublingual misoprostol, intravenous oxytocin, and intravenous methylergometrine in active management of the third stage of labor (AMTSL).METHODS:
A double-blind randomized trial of 300 women with a healthy singleton pregnancy allocated into 4 groups to receive either 400 microg or 600 microg of sublingual misoprostol, 5 IU of intravenous oxytocin, or 200 microg of intravenous methylergometrine. The primary outcome measure was blood loss in the third and fourth stage of labor; secondary measures were duration of the third stage of labor, changes in hemoglobin levels, and adverse effects.RESULTS:
Patients who received 600 microg of misoprostol had the lowest blood loss (96.05+/-21.1 mL), followed by 400 microg of misoprostol (126.24+/-49.3 mL), oxytocin (154.7+/-45.7 mL), and methylergometrine (223.4+/-73.7 mL) (P<0.01). Shortest mean duration of the third stage of labor (5.74 minutes) was with 600 microg of misoprostol, while methylergometrine had the longest (6.83 minutes) (P<0.05). Pyrexia was observed in the misoprostol groups, and raised blood pressure in the methylergometrine group (P<0.001). The 24-hour postpartum hemoglobin level was similar among the groups (P>0.05).CONCLUSION:
Administration of 600 microg of sublingual misoprostol was more effective than 400 microg of misoprostol, intravenous oxytocin, and intravenous methylergometrine for AMTSL.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Ocitócicos
/
Ocitocina
/
Misoprostol
/
Metilergonovina
Idioma:
En
Ano de publicação:
2009
Tipo de documento:
Article